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114 Poster Session II(MUD). Eligible donors included siblings sharing bothHLAhaplo-
types and haploidentical family donors with a maximum of one an-
tigen mismatch on A or B (serology) or DRB1 on the non-shared
haplotype, and MUD identical on A and B (serology), DRB1,
DQB1 before 2000 and allelic A, B, C, DRB1, and DQB1 10/10
or 9/10 allelic match from 2000.
ASCT was performed due to:
CML: 138 patients (33%),
AML: 169 patients (40%),
ALL: 72 patients (17%), all patients were high risk, mainly with
t(9;22) or relapsed disease, other indications: N 5 45 (10%).
GvHD prophylaxis was cyclosporine A (CyA) and iv methotrex-
ate. Acute GvHD$ grade II was treated with increased immunosu-
pression (CyA and methylprednisolone (2 mg/kg/day)) and steroid
refractory GvHD with ATG or other immunosuppressants. Re-
sults: The median age at transplantation increased significantly in
the study period (p 5 0.001).
The number of CML patients undergoing ASCT declined from
43% before 2000, to 21% after 2000 and 5.5% in 2006.
Overall Survival (OS):The 5 yOSwas 66% and 47% in patients
with family donors and MUD respectively.
CML: The 5 y OS for those with family donor or MUDwas 83%
and 52%.
AML: The 5 y OS for the patients with family donor: 63% and
MUD: 49%.
ALL: The 5 y OS for patients with family donor 45% and MUD
42%.
Complications registered in patients transplanted up to 2005:
GVHD: Acute GvHD occurred in 46.2%; aGvHD grade II-IV
31.2%. The incidence of chronic GvHD was 36%; 23% limited
and 13% extensive.
Infections: Proven or probable invasive fungal infections were
registered in 12.8%. CMV infection and disease was seen in
19.5% and 5.1% of the patients respectively.
Mortality: Mortality before day 100 was 11.4% and 25% in
the family donor and MUD groups, respectively. Overall non-re-
lapse mortality was 29%. Conclusion: Our results compare favor-
ably with previously published series, indicating that this
conditioning regimen remains a good option in the myeloablative
setting.308
FACTORS AND PREDICTORS ASSOCIATED WITH PERIPHERAL BLOOD
STEM CELL YIELD IN VOLUNTEER DONORS-TAIWAN EXPERIENCE
Chen, S.-H.1, Lu, C.-J.2, Wen, S.-H.3, Shyr, M.-H.2, Yang, K.-L.2.
1 Hualien Tzu-Chi Hospital, Hualien, Taiwan; 2 Buddhist Tzu-Chi
Stem Cell Center, Hualien, Taiwan; 3 Tzu-Chi University, Hualien,
Taiwan.
Background: Successful allogeneic PBSC transplantation de-
pends upon the infusion of a sufficient number of CD341 cells.
Limited information is available about the factors predicting for sat-
isfactory G-CSF-induced PBSC collection from healthy donors.
Materials andMethods:G-CSF was administered subcutaneously
daily at a dose of 8.3–11 ug/kg for 5 days for mobilization. At pres-
ent pre-CD341 cell count is the most reliable predictor of PBSC
yield. The mean CD341 concentration(106/l) was enumerated
from the final PBSC product and represented the stem cell yield
in this study. We analysed the relationship between donor
characteristics including age, body weight, BMI,WBC count, abso-
lute mononuclear cell count(MNC), circulating immature cell
count (CIC:circulating myeloblasts1promyelocytes1myelocytes1
metamyelocytes1erythroblasts), hematopoietic progenitor cell
count(HPC), platelet count and immature reticulocyte fractio-
n(IRF) and the yields of CD341 cells from 300 healthy volunteer
donors. Results: Poor mobilizer(CD341 cell\ 2  106/kg recip-
ient body weight) comprised 5% of our total volunteer PBSC do-
nors. Male donors have significant greater mean CD341 cell
yields(mean 5 2433  106/l) than that of female donors(mean 5
1670 106/l) from t-test analysis. In univariate correlation analysis,
body weight, BMI, WBC count, absolute MNC, CIC and pre-
CD341 cell count before harvest were significantly positively cor-
related with the CD341 cells, but age is negatively correlated withthe CD341 cells. The correlation analysis also showed that the
body weight, BMI, WBC count, absolute MNC, CIC and HPC
were positively correlated with pre-CD341 cell count(Pearson cor-
relation coefficient is 0.403, 0.429, 0.46, 0.199, 0.46, 0.337 respec-
tively). Conclusion: In this study, we found that gender, age, body
weight, BMI, CIC and pre-CD341 cell count were themost impor-
tant factors for predicting PBSC yields.309
PRETRANSPLANTATION ASSESSMENT OF MORTALITY (PAM) RISK
SCORE CANPREDICT COST FORPATIENTS SUBMITTEDTOAUTOLOGOUS
AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Kerbauy, F.R., Ribeiro, A.F., Toledo, C., Lisboa, L.F., Hamerschlak, N.
Hospital Israelita Albert Einstein, Sa˜o Paulo, Brazil.
Introduction: Death risk related to hematopoietic stem cell
transplantation (HSCT) is associated to donor and recipient factors.
According to theses factors a Pretransplant Assessment Mortality
(PAM) risk score was developed to predict mortality after HSCT
(Parimon T et al, 2006). Predicting mortality and cost before trans-
plant is useful to prevent complications and establish early treat-
ment. In addition, the cost of procedures related to HSCT is
usually high and its best understanting can help in projection of
the financial benefits of preventive strategies and help in negotiation
of higher reimbursements rates.Objectives: To validate PAM risk
score in our population and correlate different PAM risk groups
with transplantation cost. Material and Methods: One-hundred
and sixteen consecutive patients were retrospectively evaluated.
Twenty-seven were treated with autologous and 89 with alogeneic
HSCT from 2003 to 2006. PAM risk score was applied using the in-
ternet tool provided in the original publication (http://cdsmed.fhcr-
c.org/pam/). The transplantation cost was calculated for each
patient using the total amount spent until dischargement after en-
graftment. Classificatory variables were calculated usingChi-square
or Fisher test. Continuous variables were calculated usingWilcoxon
or Kruskal-Wallis test. Survival was compared by Kaplan-Meier
survival curves.Results:There was no difference in overall survival
between different risk groups for patients treated with alogeneic
HSCT (P5 0.10). There was a superior overall survival for patients
in low risk score treated with autologous HSCT (p 5 0.03). When
all patients were compared independently of HSCT type, there was
a significant difference in overall survival for patients in low, inter-
mediate and high risk score. Finally there was a significant statistical
difference in cost for patients in different risk groups where high
risk patients cost more than intermediate and low risk patients. (P
5 0.008).Conclusions: PAM risk score can be a useful tool to pre-
dict mortality and cost in HSCT. It can also predict cost related to
HSCT.310
RAPID ENGRAFTMENT AND LOW RATES OF GRAFT-VERSUS-HOST DIS-
EASE (GVHD) FOLLOWING REDUCED INTENSITY CONDITIONING (RIC)
WITH FLUDARABINE/BUSULFAN/ATG (FBA) AND STEM CELL TRANS-
PLANTATION (SCT) USING UNRELATED DONORS (URD)
Hamadani, M., Awan, F.T., Elder, P., Lin, T.S., Andritsos, L.,
Blum, W., Blum, K.A., Devine, S.M. Arthur G. James Cancer Hospital,
Ohio State University, Columbus, OH.
RIC regimens are increasingly used for allogeneic SCT in pa-
tients (pts) with relative contraindications for transplantation since
they promote effective engraftment of donor cells withminimal reg-
imen related toxicity. However, following URD-SCT, high rates of
acute (a) and chronic (c) GVHD have mitigated the overall benefits
of RIC. We pursued a strategy designed to enhance full donor chi-
merismwhile potentially reducing the risk of severe acute& chronic
GVHD using a RIC regimen containing FBA followed by URD
SCT in 30 consecutive high risk pts. Selection criteria included
age .55 yrs, prior autograft, and/or high co-morbidity index (me-
dian 2, range 0–4). There were 24 male and 6 female pts with a me-
dian age of 53 years (range 22–66 yrs). Diagnoses included AML
Poster Session II 115(n 5 10), NHL (n 5 7), Hodgkin’s lymphoma (n 5 6), advanced
CML (n5 4), and advanced CLL (n5 4). 9 pts had previously un-
dergone autografting. 80% received HLA-identical grafts. All pts
were conditioned with fludarabine (30 mg/m2/day, days -7 to -3),
busulfan (0.8 mg/kg/dose IV  8 doses) and rabbit ATG (2.5 mg/
kg/day, days -4 to -2) followed by micro-dose methotrexate and ta-
crolimus. Stem cell source included peripheral blood (n 5 26) or
bone marrow (n 5 4). All pts engrafted neutrophils and platelets
promptly (median 15 and 16 days, respectively). There were no pri-
mary graft failures. Rates of grade II-IV and III-IV aGVHD were
43% (n5 13) and 23% (n5 7) respectively. 9 pts (30%) developed
cGVHD but extensive cGVHD was seen in only 10% (n5 3). Day
100TRMwas 10% (n5 3). CMV and EBV reactivation occurred in
30% (n 5 9) and 20% (n 5 6) respectively. 2 pts developed PTLD
requiring rituximab. 3 pts had BK-virus associated hemorrhagic
cystitis. Chimerism analysis showed 100% donor CD331 at all
time points (days 30, 60, 100) and median donor CD31 chimerism
of 94% at day 130 and 100% at day 1100. One pt had secondary
graft failure. 23 pts (76%) were in CR after SCT. Kaplan-Meier es-
timates of overall survival (OS) and progression free survival (PFS)
at 1 year are 62% and 43% respectively. OS (P 5 0.95) and PFS (P
5 0.65) was not statistically significant between recipients of
matched andmismatched grafts. In conclusion, FBA and tacrolimus
basedGVHDprophylaxis achieved rapid donor chimerism and a fa-
vorably low incidence of TRM and cGVHD despite being tested in
poor risk pts. However the rates of EBV reactivation and disease re-
lapse warrant further exploration of this approach using lower doses
of ATG (e.g. 5–6 mg/kg total dose).311
ALLOGENIC STEM CELL TRANSPLANTATION IN PATIENTS WITH AC-
QUIRED APLASTIC ANEMIA AND FANCONNI ANEMIA: A SINGLE CENTER
EXPERIENCE OVER 11 YEARS
Rosales, C., Abello, V., Esguerra, H.J., Pedraza, E., Linares, A.,
Rosales, M.L. Clınica de Marly, Bogota, Colombia.
We performed a retrospective analysis, of allogenic stem cell
transplantation (allo-SCT) results, in 40 patients with diagnosis of
acquired aplastic anemia or Fanconni Anemia, in a transplant center
in Bogota, Colombia, between 1996 and 2007.
During that period, 42 transplants were performed in 40 patients.
28 (70%) acquired aplastic anemia and 12 (30%) Fanconni’s Ane-
mia. 17 (42.5%) female/25 (62.5%) male. Mean age was 22 years
(4–57).
Stem cells were obtained from peripheral blood in 36 (90%) and
from bone marrow in 6 (15%). The majority of patients were of
high risk; themean time fromdiagnosis to transplantwas 27.8months
(2–141) and 57.5% of them had received more than 20 transfusions
before transplantation. Patients were conditioned with Cy-ATG in
24 (57.1%), high doseCyclophosphamide (Cy) in 11 (26.2%), fludar-
abine-Cy-ATG in 3 (7.14%) and Alemtuzumab-Cy in 4 (9.52%).
Mean CD341 cell dose was 3.3 (1.08–6.66), TNC: 9.7 (1.2–
59.2).
Neutrophil engraftment was achieved at day 116 (3–54) post-
transplantation.
At a mean follow up of 19.5 months (7–128), overall survival is
65%.
Comparison of results of different conditioning regimens shows
that overall survival for patients conditioned with Cy alone is disap-
pointing, 8/11 patients died, 6 due toGVHDand 2 due to infection.
After adding ATG to Cy, mortality due to GVHDwas significantly
reduced. Only 7/24 patients died, GVHD was the cause of death
only in 2. Infection was the cause of death in other 4. 2 patients
had secondary graft failure, one died. The other received a second
transplant and is alive with mixed chimerism, but free of transfusion
support.
Of 4 patients treated with alemtuzumab containing regimens, 3
had secondary graft failure, 2 died, and one received a second trans-
plant successfully.
On this group of patients Cy-ATGwas the best conditioning reg-
imen in terms of overall survival and GVHD incidence. The major-
ity of patients in this cohort were remitted to transplant late in their
disease, early treatment will probably improve the outcomes, as it
has been confirmed in other papers.312
DOG LEUKOCYTE ANTIGEN (DLA)-IDENTICAL SIBLING CORD BLOOD
TRANSPLANTATION (CBT) FOLLOWING MYELOABLATIVE TOTAL
BODY IRRADIATION (TBI)
Lesnikov, V.1, Baran, S.1, Abrams, K.1, Zellmer, S.1, Yang, Y.-J.1,
Heimfeld, S.1, Lesnikova, M.1, Nash, R.A.1,2, Georges, G.E.1,2. 1 Fred
Hutchinson Cancer Research Center, Seattle, WA; 2 University of
Washington, Seattle, WA.
Cord blood (CB) is increasingly used for hematopoietic cell
transplantation due to its rapid availability and less stringent HLA
matching requirements. However, low cell dose of CB units and de-
layed engraftment remain significant obstacles for increased use of
CBT in adults. We aim to develop a large animal model of CBT
by using outbred dogs to improve the understanding of engraftment
across histocompatibility barriers and cell dose limitations of CBT.
We harvested and cryopreserved individual units of canine CB ob-
tained from litters following Caesarian section at day 54 to 60 of
gestation.We asked if single or multiple units of DLA-identical sib-
ling CB could engraft in DLA-identical recipient dogs. Eight adult
dogs received 920 cGy TBI followed by intravenous infusion of
thawed CB, either a single CB unit (n 5 3) or multiple [2 to 4]
CB units (n 5 5) with a combined total nucleated cell (TNC)
dose range 0.3–2.6  107/kg. Transplanted total CD341 cell dose
was 0.2–2.5  105/kg. Postgrafting immunosuppression was cyclo-
sporine 1 mycophenolate mofetil for 35 and 28 days, respectively.
G-CSF was given until recovery of neutrophil counts. Three dogs
died on days 13–17 due to neutropenic sepsis. Five dogs engrafted
and survived; and are currently 265–621 days after CBT. Sustained
neutrophil recovery.1000/mLoccurred 29–35 days after CBT, and
platelet recovery .20,000/mL was 38–84 days after CBT. Monthly
chimerism analysis was assessed by PCR using informative microsa-
tellite markers. Among each of the 4 surviving recipients of multiple
unit CBT, all transplanted donor CB units contributed to hemato-
poiesis with sustained multi-donor chimerism. However, in all 4
dogs, 1 of the CB units eventually dominated hematopoiesis with
sustained 75–95% donor chimerism. In all cases the dominant CB
unit had the highest TNC dose. There was no acute or chronic
GVHD. From 3–8months after CBT, immune reconstitution stud-
ies normalized including T cell proliferation allo-stimulation index,
1o and 2o immune response to sheep red blood cells and recovery of
the absolute number of CD4 and CD8 T-cell subsets. In summary,
cryopreserved DLA-identical CB successfully engrafted and pro-
vided durable hematopoietic recovery. There was stable multi-do-
nor chimerism and the CB unit with the greatest TNC dose
predicted the dominant donor graft. The approximate minimum
cell dose threshold for successful engraftment of a single CB unit
with this conditioning regimen model was 0.8  107 TNC/kg.313
TACROLIMUS DOSING IN ALLOGENEIC HEMATOPOIETIC STEM-CELL
TRANSPLANTATION RECIPIENTS RECEIVING VORICONAZOLE
Trifilio, S.M., Pi, J., Singhal, S., Frankfurt, O., Evens, A., Gordon, L.,
Tallman, M., Winter, J., Williams, S., Mehta, J. Northwestern Univer-
sity, Chicago.
Tacrolimus (TAC) is primarily metabolized by the CYP450 3A4
isoenzyme. Voriconazole, often used to prevent fungal infections af-
ter allogeneic HSCT, is metabolized by the CYP450 3A4, 2C9 and
2C19 isosenzymes. Clinical trials in healthy volunteers have shown
significant drug interactions between the two requiring TAC dose
reduction. Ordinarily, TAC is started at the dose of 0.03 mg/kg
IV daily on day -1. After starting it at this dose and having to reduce
the dose substantially within 2–3 days in all patients receiving con-
comitant voriconazole 200 mg twice daily orally from day 0, we im-
plemented a simple, preemptive TAC dose reduction strategy to
maintain steady-state levels between 5 and 15 ng/mL. As a first
step, IV TAC was initiated at the reduced dose of 0.022 mg/kg/
day. As a second step, dose was reduced by 30–40% if the steady-
state level 48 h after initiation of TAC (day 11) was between 7
and 10 ng/mL, and by 40–50% if the level was between 10 and 15
ng/mL. No change was made if the level was\7 ng/mL. Subse-
quently, levels were monitored 2–3 times a week and the dose
